By Katherine Hamilton
Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025.
The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months.
The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year.
Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet.
Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:08 ET (13:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。